|

Eloralintide Clinical Trials

5 actively recruiting trials across 4 locations

Also known as: LY3841136

Pipeline

Phase 2: 1Phase 3: 4

Top Sponsors

  • Eli Lilly and Company5

Indications

  • Diabetes4
  • Overweight4
  • Obesity4
  • Osteoarthritis1
  • Weight Loss1

Birmingham, Alabama2 trials

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Birmingham Clinical Research

Phase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Birmingham Clinical Research

Phase 3

Mobile, Alabama1 trial

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

AMR Clinical

Phase 3

Tuscaloosa, Alabama1 trial

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

MFA Clinical Research

Phase 3

Gilbert, Arizona1 trial

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.